Penile cancer (PC) is a rare tumor, and therapeutic options are limited for this disease, with an overall 5-year overall survival around 65-70%. Adjuvant therapy is not recommended for patients with N0-1 disease, despite up to 60% of these patients will die within 5 years from…
Source: Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study
Tuesday, July 2, 2013
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment